28.28EUR+0.07%Mkt Cap: 1.02B EURP/E: —Last update: 2026-06-01
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting in…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.02B EUR
Enterprise Value955.57M EUR
Revenue (TTM)32.44M EUR
Gross Profit25.54M EUR
Net Income (TTM)-18.44M EUR
Revenue/Share1.026 EUR
Last Price28.28 EUR
Fiscal Year EndMar 2025
MR QuarterSep 2025
Employees145
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004065605
Valuation
P/E (Trailing)—
P/E (Forward)159.53
PEG—
EV/EBITDA-99.86
EV/Revenue29.46
P/S31.28
P/B-30.55
EPS (TTM)-0.61
EPS (Forward)0.18
52W Range
15.0054% of range39.68
52W High39.68 EUR
52W Low15.00 EUR
Profitability
Gross Margin100.00%
Oper. Margin-46.74%
EBITDA Margin-29.50%
Profit Margin-72.19%
ROE112.65%
ROA-20.38%
Growth
Revenue Growth49.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF19.46M EUR
CapEx (TTM)1.66M EUR
FCF Margin-44.22%
FCF Yield-1.41%
Net Debt20.09M EUR
Net Debt/EBITDA-2.10
Balance Sheet
Debt/Equity-3.59
Current Ratio2.88
Quick Ratio2.83
Book Value/Sh-0.9250 EUR
Cash/Share1.616 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)34.68 EUR
Target Range29.20 EUR – 43.00 EUR
# Analysts10
Ownership
Shares Out.35.91M
Float30.23M
Insiders35.05%
Institutions32.01%
Technical
SMA 5024.45 (+15.7%)
SMA 20025.36 (+11.5%)
Beta1.00
S&P 52W Chg27.94%
Avg Vol (30d)116.97K
Avg Vol (10d)89.44K
Technical Indicators
RSI (14)62.8
MACD0.8359
MACD Signal0.8350
MACD Hist.+0.0010
BB Upper28.97 EUR
BB Middle26.86 EUR
BB Lower24.76 EUR
BB Width15.70%
ATR (14)1.348 EUR
Vol Ratio (20d)3.60x